2020
DOI: 10.1097/mca.0000000000000825
|View full text |Cite
|
Sign up to set email alerts
|

Effect of intracoronary tirofiban following aspiration thrombectomy on infarct size, in patients with large anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Abstract: Background Myocardial recovery following primary percutaneous coronary intervention is often suboptimal despite of restoration of thrombolysis in myocardial infarction (TIMI) 3 flow, in part due to thrombus embolization which results in impairing microvascular reperfusion besides increasing infarct size. The purpose of the present study was to estimate the effect of aspiration thrombectomy followed by intracoronary delivery of tirofiban on decreasing the infarct size utilizing cardiac MRI (cMR) in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(8 citation statements)
references
References 25 publications
0
8
0
Order By: Relevance
“…Glycoprotein IIb/IIIa inhibitors can prevent platelet aggregation and reduce thrombotic events in patients with acute coronary syndrome ( 34 ). Randomized clinical trials have suggested that intracoronary administration of tirofiban to achieve a high local concentration of the drug can reverse no-flow phenomena and attenuate microvascular obstruction in patients with STEMI undergoing primary PCI ( 19 , 35 37 ). Our finding that myocardial reperfusion is improved by intracoronary infusion of tirofiban during primary PCI for acute STEMI is consistent with the above studies and with numerous other investigations evaluating the effects of intracoronary administration of glycoprotein IIb/IIIa inhibitors during PCI ( 14 19 ).…”
Section: Discussionmentioning
confidence: 99%
“…Glycoprotein IIb/IIIa inhibitors can prevent platelet aggregation and reduce thrombotic events in patients with acute coronary syndrome ( 34 ). Randomized clinical trials have suggested that intracoronary administration of tirofiban to achieve a high local concentration of the drug can reverse no-flow phenomena and attenuate microvascular obstruction in patients with STEMI undergoing primary PCI ( 19 , 35 37 ). Our finding that myocardial reperfusion is improved by intracoronary infusion of tirofiban during primary PCI for acute STEMI is consistent with the above studies and with numerous other investigations evaluating the effects of intracoronary administration of glycoprotein IIb/IIIa inhibitors during PCI ( 14 19 ).…”
Section: Discussionmentioning
confidence: 99%
“…The left anterior descending (LAD) artery was the infarct-related artery in 32% to 80% of patients in six studies [ 78 , 80 82 , 85 , 88 ]. Five studies enrolled patients with anterior STEMI only ( Table 2 ) [ 79 , 83 , 84 , 86 , 87 ].…”
Section: Resultsmentioning
confidence: 99%
“…Door-to-balloon time ranged from 17.8 to 120 minutes. Radial access during coronary angiography was used in four studies [ 77 , 80 , 84 , 86 ], femoral in two [ 78 , 87 ], and the access approach was not stated in the remaining ones. As a result of identifying various pharmacological interventions, the studies were divided into three groups; thrombolytics (Group 1), GPI (Group 2), and GPI plus AT (Group 3).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations